Across TCGA pan-cancer cohorts, CDRT4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CDRT4 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in brain lower grade glioma (LGG), where higher CDRT4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDRT4 expression acts as an unfavorable survival marker.
LGG are the cancer types where CDRT4 Mutation most reproducibly stratifies survival.